High Growth Tech Stocks To Explore In February 2025

The Australian market has recently experienced a downturn, with the ASX200 down 0.36% amid negative reactions to impending U.S. tariffs on Australian aluminium and steel, while IT and Technology sectors have notably declined by 1.2%. In this challenging environment, identifying high growth tech stocks involves looking for companies that demonstrate resilience and adaptability in the face of economic pressures and sector-specific challenges.

Top 10 High Growth Tech Companies In Australia

Name	Revenue Growth	Earnings Growth	Growth Rating
Clinuvel Pharmaceuticals	21.39%	26.17%	★★★★★★
Pureprofile	14.31%	71.53%	★★★★★☆
Adherium	86.80%	73.66%	★★★★★★
Pro Medicus	20.97%	22.67%	★★★★★★
Gratifii	40.96%	103.72%	★★★★★★
AVA Risk Group	25.54%	77.32%	★★★★★★
Mesoblast	49.04%	54.89%	★★★★★★
Pointerra	56.62%	126.45%	★★★★★★
Wrkr	44.16%	98.46%	★★★★★★
Opthea	52.56%	60.35%	★★★★★★

Click here to see the full list of 52 stocks from our ASX High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Dropsuite (ASX:DSE)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Dropsuite Limited operates a global cloud-based software platform, with a market capitalization of A$403.99 million.

Operations: Dropsuite Limited generates its revenue primarily from the provision of backup services, amounting to A$35.46 million. The company operates a cloud-based software platform on a global scale.

Dropsuite, recently acquired by NinjaOne for AUD 410 million, showcases robust financial health with a notable annual revenue growth of 21.1%, outpacing the Australian market average of 6%. Despite a dip in profit margins from 7.6% to 2.9% last year, the company is poised for significant earnings expansion at an annual rate of 34.4%. This acquisition underlines Dropsuite's potential in the competitive software sector, particularly as its innovative solutions continue to attract strategic interest and investment, signaling promising prospects for future growth and market presence.

• Click to explore a detailed breakdown of our findings in Dropsuite's health report.

• Gain insights into Dropsuite's historical performance by reviewing our past performance report.

Nuix (ASX:NXL)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Nuix Limited offers investigative analytics and intelligence software solutions across various regions including the Asia Pacific, the Americas, Europe, the Middle East, and Africa, with a market cap of approximately A$1.59 billion.

Operations: Nuix Limited generates revenue primarily from its Software & Programming segment, amounting to A$220.62 million. The company focuses on providing software solutions for investigative analytics and intelligence across multiple regions globally.

Nuix, a standout in the Australian tech scene, has demonstrated impressive financial agility with an expected annual revenue growth of 14.2%, surpassing the national average of 6%. This growth is complemented by a forecasted earnings increase of 40.3% per year, highlighting its potential to outperform market expectations significantly. Despite facing challenges from one-off losses totaling A$6.4 million last fiscal year, Nuix's strategic focus on enhancing its software capabilities and expanding market reach—evidenced by robust half-yearly revenue projections between A$104 million and A$106 million—positions it well for sustained growth in the competitive tech landscape.

• Click here and access our complete health analysis report to understand the dynamics of Nuix.

• Review our historical performance report to gain insights into Nuix's's past performance.

Opthea (ASX:OPT)

Simply Wall St Growth Rating: ★★★★★★

Overview: Opthea Limited is a clinical-stage biopharmaceutical company focused on developing and commercializing drugs for eye diseases in Australia and the United States, with a market capitalization of A$1.39 billion.

Operations: Opthea generates revenue primarily from its medical technology and healthcare segment, amounting to $0.26 million. As a clinical-stage company, it focuses on drug development for eye diseases across Australia and the United States.

Opthea, an emerging name in the biotech sector, is making significant strides with a projected annual revenue growth of 52.6%, far surpassing Australia's average tech growth rate. This performance is underpinned by its innovative focus on treatments for diabetic macular edema, highlighted in recent trials showing promising results with sozinibercept therapy. Despite current unprofitability, Opthea's aggressive R&D investment aligns with its strategy to meet growing healthcare demands, particularly in ophthalmology—a field ripe for technological advancements and increased patient need. With revenue just shy of $1 million and expectations set on becoming profitable within three years, Opthea represents a dynamic player poised to capitalize on specialized healthcare solutions.

• Take a closer look at Opthea's potential here in our health report.

• Learn about Opthea's historical performance.

Key Takeaways

• Click here to access our complete index of 52 ASX High Growth Tech and AI Stocks.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com